These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 19509351)

  • 1. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
    Cooperberg MR; Broering JM; Carroll PR
    J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
    Herlemann A; Cowan JE; Washington SL; Wong AC; Broering JM; Carroll PR; Cooperberg MR
    Eur Urol; 2024 Jun; 85(6):565-573. PubMed ID: 37858454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients.
    Yoshida T; Nakayama M; Takeda K; Arai Y; Kakimoto K; Nishimura K
    Urol Int; 2012; 89(1):45-51. PubMed ID: 22441013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.
    Beckmann K; O'Callaghan M; Vincent A; Roder D; Millar J; Evans S; McNeil J; Moretti K
    ANZ J Surg; 2018 Mar; 88(3):E183-E188. PubMed ID: 28471003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
    Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
    Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
    Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
    Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
    Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
    J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA density does not improve predictive accuracy of the UCSF-CAPRA score.
    Parker R; Bell A; Chang K; Greenberg S; Washington SL; Cowan JE; Carroll PR; Cooperberg MR
    Prostate; 2023 Jul; 83(10):922-928. PubMed ID: 37078628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.
    Budäus L; Isbarn H; Tennstedt P; Salomon G; Schlomm T; Steuber T; Haese A; Chun F; Fisch M; Michl U; Heinzer H; Huland H; Graefen M
    BJU Int; 2012 Dec; 110(11):1714-20. PubMed ID: 22520619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort.
    Tilki D; Mandel P; Schlomm T; Chun FK; Tennstedt P; Pehrke D; Haese A; Huland H; Graefen M; Salomon G
    J Urol; 2015 Jun; 193(6):1970-5. PubMed ID: 25498570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
    Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
    Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy.
    Cooperberg MR; Hilton JF; Carroll PR
    Cancer; 2011 Nov; 117(22):5039-46. PubMed ID: 21647869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
    Cooperberg MR; Vickers AJ; Broering JM; Carroll PR
    Cancer; 2010 Nov; 116(22):5226-34. PubMed ID: 20690197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series.
    Loeb S; Carvalhal GF; Kan D; Desai A; Catalona WJ
    Urol Oncol; 2012 Sep; 30(5):584-9. PubMed ID: 20822930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.
    Bill-Axelson A; Holmberg L; Garmo H; Taari K; Busch C; Nordling S; Häggman M; Andersson SO; Andrén O; Steineck G; Adami HO; Johansson JE
    N Engl J Med; 2018 Dec; 379(24):2319-2329. PubMed ID: 30575473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.